SRTS (Sensus Healthcare) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SRTS Sensus Healthcare Inc SRTS
73 GF Score
Price $3.04
GF Value $2.72
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sensus Healthcare Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

SRTS
73GF Score
Sensus Healthcare Inc SRTS
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sensus Healthcare (SRTS) Overvalued in 2026?

Based on GuruFocus' analysis, Sensus Healthcare stock appears to be overvalued. The current stock price of $3.04 is trading 11.8% above its estimated GF Value™ of $2.72. GuruFocus considers Sensus Healthcare to be Modestly Overvalued.

Key valuation signals for SRTS:

  • Interest Received:
  • GF Value™: $2.72 vs. price of $3.04 (11.8% above fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the SRTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sensus Healthcare Business Description

Other Exchanges 5TX:Germany
Address 851 Broken Sound Parkway, NW, Suite 215, Boca Raton, FL, USA, 33487
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
73GF Score

Get the complete analysis for SRTS

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.04
Price
$2.72
GF Value